Why Arena Pharmaceuticals Shares Slimmed Down

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of obesity-fighting biotech Arena Pharmaceuticals (NASDAQ: ARNA  ) shed as much as 11% today following its first-quarter earnings results and the company announcing the withdrawal of its European Union marketing application for Belviq.

So what: For the quarter, Arena Pharmaceuticals saw its loss narrow to just $0.09 from $0.18 in the year-ago period as revenue moved modestly higher to $2.37 million. Unfortunately, analysts had expected the Drug Enforcement Agency to have labeled Belviq by now and for Arena to have accepted a milestone payment from marketing partner Eisai Pharmaceuticals. Given that neither has happened, Arena's results were well short of the $68.3 million in revenue and $0.20 profit that the Street had expected.

Furthermore, Arena Pharmaceuticals pulled its application for marketing authorization in the EU in order to take its time to better understand what the EU's objections are to the drug. If you recall, VIVUS' Qsymia (known as Qsiva in Europe) failed to gain marketing approval in the EU last year due to long-term concerns about the drugs' effect on the heart and blood vessels.

Now what: Now we wait some more -- something Arena shareholders should be fairly good at by now. The DEA labeling will be a big boost as it'll clear the way for Belviq to make it onto pharmacy shelves and trigger a milestone payment from Eisai. Like VIVUS, I wouldn't expect sales to come roaring out of the gate, however, I do expect a sales ramp-up to occur more quickly than what we saw with VIVUS simply on the fact that Arena has a gigantic marketing partner in Eisai.

Craving more input? Start by adding Arena Pharmaceuticals to your free and personalized watchlist so you can keep up on the latest news with the company.

Got Arena? Get smart.
In the Fool's premium research report, senior biotech analyst Brian Orelli takes you through a comprehensive look at this contentious stock, including its massive opportunity, potential pitfalls, and key reasons to both buy and sell. To find out more about Arena, click here to access your report today.


Read/Post Comments (2) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On May 03, 2013, at 5:54 PM, Paulson545 wrote:

    Legendary investor Dr Frost Phillip has been buying shares of OPK ans SFES. High risk High reward.

  • Report this Comment On May 05, 2013, at 11:02 AM, Foreeverlong wrote:

    The PPS of Arena will be entirely based on sales. It is extraordinary that the DEA has taken so long to label Belviq, but it will come in time. Keep in mind that Belviq is not a one trick pony, and can be taken for both weight loss and treatment of Type II diabetes. The recent shakeout has no doubt removed more shares from the hands of retail investors and placed them into the hands of the institutions. The positive story continues with Arena's Belviq. No one bought the stock based on EU approval. It's just a buying opportunity for those that believe.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2407346, ~/Articles/ArticleHandler.aspx, 9/30/2014 8:06:40 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement